Biogen (BIIB) Operating Expenses (2009 - 2026)

Biogen has reported Operating Expenses for 18 years, with the latest figure at $2.6 billion in Q2 2026.

• On a quarterly basis, Operating Expenses rose 36.92% year-over-year to $2.6 billion in Q2 2026; TTM through Jun 2026 was $9.0 billion, a 9.97% increase from a year earlier, with the FY2025 full-year figure at $8.3 billion, up 7.26% from the prior year.
• Operating Expenses was $2.6 billion for Q2 2026 at Biogen, up from $2.1 billion in the prior quarter.
• The five-year high for Operating Expenses was $2.7 billion in Q3 2023, with the low at $1.1 billion in Q3 2022.
• Average Operating Expenses over 5 years is $2.0 billion, with a median of $2.0 billion recorded in 2023.
• The sharpest annual moves came in 2022 and 2023: Operating Expenses plunged 54.28% in 2022, then surged 134.88% in 2023.
• Over 5 years, Operating Expenses stood at $1.9 billion in 2022, then advanced by 7.96% to $2.1 billion in 2023, then grew by 3.27% to $2.2 billion in 2024, then climbed by 7.96% to $2.3 billion in 2025, then advanced by 11.48% to $2.6 billion in 2026.
• The last three Operating Expenses figures came in at $2.6 billion (Q2 2026), $2.1 billion (Q1 2026), and $2.3 billion (Q4 2025), per Business Quant data.